Last reviewed · How we verify
Control: Placebo administration
Placebo administration produces therapeutic effects through patient expectation and psychological mechanisms rather than pharmacological action.
Placebo administration produces therapeutic effects through patient expectation and psychological mechanisms rather than pharmacological action. Used for Used as control arm in clinical trials across all therapeutic areas.
At a glance
| Generic name | Control: Placebo administration |
|---|---|
| Also known as | placebo administration (sodium chloride) |
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance or sham procedure that elicits clinical benefit via the placebo effect, which involves expectation, conditioning, and psychobiological pathways. It serves as a control comparator in clinical trials to distinguish true drug efficacy from non-specific therapeutic effects. The mechanism is primarily psychological and neurobiological rather than chemical.
Approved indications
- Used as control arm in clinical trials across all therapeutic areas
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- The RECLAIM Study. (NA)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Study of TGM-312-SC01 in Healthy Participants and Adults With MASH (PHASE1, PHASE2)
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (PHASE3)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: